Hearing loss following the application of topical neomycin.
Profound, irreversible ototoxicity has been reported following oral and topical neomycin therapy. Preexisting renal disease is a known risk factor for this adverse effect. In spite of the potential hazards of this drug, it continues to be used widely both orally and topically. This is a report of a severe, permanent hearing deficit that occurred in a patient with chronic renal failure. The patient, who had developed decubitus ulcers, was treated for three weeks with topical 1% neomycin solution applied in gauze-soaked bandages. Regular hemodialysis failed to prevent this adverse effect. Caution should be exercised in selecting patients to receive prolonged neomycin therapy.
Johnson
C A
CA
School of Pharmacy, University of Wisconsin-Madison.
D000287:Administration, Topical; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D008875:Middle Aged; D009355:Neomycin / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D003668:Pressure Ulcer / Q000150:complications / Q000188:drug therapy
D009355:Neomycin